agilon health, inc. Files 8-K Report

TL;DR

AGLN filed an 8-K, standard disclosure, no major news yet.

AI Summary

On November 19, 2024, agilon health, inc. filed an 8-K report. The filing primarily serves as a notification of Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, but the filing indicates a standard disclosure process.

Why It Matters

This 8-K filing indicates that agilon health, inc. is making a regulatory disclosure and submitting financial statements and exhibits to the SEC, which is a standard procedural event for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosure and exhibits, not indicating any immediate negative or positive material events.

Key Players & Entities

• agilon health, inc. (company) — Registrant
• 0001628280-24-048345 (filing_id) — Accession Number
• November 19, 2024 (date) — Date of Report
• 6210 E Hwy 290, Suite 450 Austin, TX 78723 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — ch registered Common stock, par value $0.01 per share AGL The New York Stock Exchan

Filing Documents

• agl-20241119.htm (8-K) — 28KB
• exhibit991investorpresen.htm (EX-99.1) — 15KB
• exhibit991investorpresen001.jpg (GRAPHIC) — 78KB
• exhibit991investorpresen002.jpg (GRAPHIC) — 245KB
• exhibit991investorpresen003.jpg (GRAPHIC) — 97KB
• exhibit991investorpresen004.jpg (GRAPHIC) — 90KB
• exhibit991investorpresen005.jpg (GRAPHIC) — 82KB
• exhibit991investorpresen006.jpg (GRAPHIC) — 101KB
• exhibit991investorpresen007.jpg (GRAPHIC) — 94KB
• exhibit991investorpresen008.jpg (GRAPHIC) — 70KB
• exhibit991investorpresen009.jpg (GRAPHIC) — 69KB
• 0001628280-24-048345.txt ( ) — 1501KB
• agl-20241119.xsd (EX-101.SCH) — 2KB
• agl-20241119_lab.xml (EX-101.LAB) — 22KB
• agl-20241119_pre.xml (EX-101.PRE) — 24KB
• agl-20241119_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. agilon health, inc. will participate in the 2024 Wolfe Research Healthcare Conference, including a presentation on Tuesday, November 19th at 2:20 PM Eastern Time. A copy of the investor presentation is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. Interested investors and other parties may listen to a simultaneous webcast of the presentation on Tuesday, November 19th by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. The information set forth in this Item 7.01 of this Current Report on Form 8-K and the related information in Exhibit 99.1 attached hereto is being furnished herewith, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing with, the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference therein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Presentation dated November 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. agilon health, inc. Date: November 19, 2024 By: /s/ JEFFREY SCHWANEKE Jeffrey Schwanke Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR